scholarly journals А retrospective long-term analysis of the epidemiology and features of drug-induced headache

2000 ◽  
Vol XXXII (1-2) ◽  
pp. 83-83
Author(s):  
S. Evers ◽  
B. Suhr ◽  
B. Bauer ◽  
K. Grotemeyer ◽  
I. Husstedt

Drug (abusal) headache is a manifestation of adverse reactions to many drugs used to treat primary headaches.

1999 ◽  
Vol 246 (9) ◽  
pp. 802-809 ◽  
Author(s):  
S. Evers ◽  
Birgit Suhr ◽  
Birgit Bauer ◽  
Karl-Heinz Grotemeyer ◽  
Ingo-W. Husstedt

2020 ◽  
Vol 12 (4) ◽  
pp. 73-78
Author(s):  
V. V. Osipova ◽  
K. V. Skorobogatykh ◽  
A. R. Artemenko ◽  
A. V. Sergeev

The paper deals with the actual problem of managing patients with drug-induced headache (DIH) in patients with primary headaches. It describes a clinical case of extremely severe DIH in a patient with chronic tension headache (TH). The paper analyzes the typical and atypical manifestations of DIH and discusses the role of prolonged stress in the development of TH. Special attention is paid to the problems with therapy and compliance during a long-term follow-up of the patient. Based on the clinical features of pain syndrome in the described patient, the authors suggest for the first time that the use of extremely high number of daily doses of combined narcotic analgesics for many years can result in recurrent DIH statuses. The paper discusses whether it is expedient to introduce the concept “DIH severity” and whether an additional clinical parameter “the number of doses of painkillers per month” can be of informative value, which has not been proposed yet in the literature. All the issues given in the paper are conjectural and are raised by the authors for further investigation of the DIH problem.


2020 ◽  
Vol 24 (1-2) ◽  
pp. 40-43
Author(s):  
A.V. Lavrenko ◽  
Ya.M. Avramenko ◽  
O.A. Borzykh ◽  
I.P. Kaidashev

Aims: Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) has various mechanisms and represents different clinical syndromes from anaphylaxis to severe bronchospasm. The prevalence of aspirin hypersensitivity among patients with asthma and nasal polyps reaches 25.6%. Respiratory reactions associated with aspirin or other NSAIDs are not immunological. The basis of these reactions is non-allergic hypersensitivity of the cross-reactive type. Desensitization followed by long-term aspirin therapy is an effective method of treating hypersensitivity to aspirin or other NSAIDs. Using aspirin 600-1200 mg/day can significantly alleviate the symptoms of asthma, allergic rhinitis. Methods: We successfully applied aspirin desensitization for method of patients with hypersensitivity to NSAIDs. According to the method, an hour before the desensitization, daily montelukast 10 mg was taken orally, then aspirin every 3 hours. Results: Three patients underwent desensitization of aspirin. The dose was selected individualy depending on the clinical manifestations of drug-induced adverse reactions (AR). ARs during desensitization were treated by iv dexamethasone administration. Subsequent doses did not cause AR. Doses of aspirin were increased to a maximum of 1250 mg daily, and were continued for the long-term use. Conclusion: It is possible to conclude that the initial dose of aspirin should be 16-40mg; it is possible to increase the dose if the initial dosage is well tolerated; symptoms of moderate intolerance are treated by 4-8 mg iv dexamethasone; prior to desensitization, we recommended to use montelukast 10 mg, it is safe to practice desensitization of aspirin according to a personalized technique by a specialist in an intensive care unit.


2001 ◽  
Vol 45 (4) ◽  
pp. 229-235 ◽  
Author(s):  
G. Fritsche ◽  
A. Eberl ◽  
Z. Katsarava ◽  
V. Limmroth ◽  
H.C. Diener

Cephalalgia ◽  
1999 ◽  
Vol 19 (1) ◽  
pp. 44-49 ◽  
Author(s):  
B Suhr ◽  
S Evers ◽  
B Bauer ◽  
I Gralow ◽  
KH Grotemeyer ◽  
...  

Cephalalgia ◽  
1999 ◽  
Vol 19 (1) ◽  
pp. 44-49 ◽  
Author(s):  
B Suhr ◽  
S Evers ◽  
B Bauer ◽  
I Gralow ◽  
KH Grotemeyer ◽  
...  

Drug-induced headache is a well-known complication of the treatment of primary headache disorders, and its successful management is only possible by withdrawal therapy. However, it is unknown whether ambulatory or stationary withdrawal is the therapy preferred. We conducted a prospective study on the outcome of stationary versus ambulatory withdrawal therapy in patients with drug-induced headache according to the International Headache Society criteria. Out of 257 patients with the diagnosis of drug-induced headache during the study period, 101 patients (41 after ambulatory and 60 after stationary withdrawal therapy) could be followed up for 5.9 ± 4.0 years. The total relapse rate after successful withdrawal therapy was 20.8% (14.6% after ambulatory and 25.0% after stationary withdrawal therapy, p <0.2). The main risk factors for a relapse were male sex (OR=3.9, CI=1.3-11.6), intake of combined analgesic drugs (OR=3.8, CI=1.4-10.3), administration of naturopathy (OR=6.0, CI=1.2-29.3), and a trend to tension-type headache as the primary headache disorder (OR=1.9, CI=0.6-53.0). Our data suggest that neither the method of withdrawal therapy nor the kind of analgesic and other antimigraine drugs has a major impact on the long-term result after successful withdrawal therapy. Patients with risk factors according to our findings should be informed and monitored regularly, and combined drugs should be avoided. Furthermore, our data suggest that there is a need for research on individual psychological and behavioral risk factors for relapse after successful withdrawal therapy in drug-induced headache.


Sign in / Sign up

Export Citation Format

Share Document